Covered recipient · General Payments record
SHELBI ATRASH
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$712,187.69
- Reported across 205 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $496,407.50 | 19 |
| Food and Beverage | $609.17 | 7 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $488,422.69 | 14 |
| Janssen Biotech, Inc. | $2,286.34 | 4 |
| E.R. Squibb & Sons, L.L.C. | $2,130.00 | 1 |
| Janssen Scientific Affairs, LLC | $1,907.50 | 1 |
| Karyopharm Therapeutics Inc. | $1,222.50 | 2 |
| GlaxoSmithKline, LLC. | $800.00 | 1 |
| GENZYME CORPORATION | $187.64 | 2 |
| Acerta Pharma LLC | $60.00 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (26)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $60.00 | 12/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105560692 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,130.00 | 11/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101383016 | CMS |
| GENZYME CORPORATION | $26.11 | 06/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139797606 | CMS |
| GENZYME CORPORATION | $161.53 | 12/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139797642 | CMS |
| GlaxoSmithKline, LLC. | $800.00 | 01/04/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1116369619 | CMS |
| Janssen Biotech, Inc. | $2,047.50 | 01/03/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1078820334 | CMS |
| Janssen Biotech, Inc. | $40.91 | 06/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078820951 | CMS |
| Janssen Biotech, Inc. | $52.94 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078820986 | CMS |
| Janssen Biotech, Inc. | $144.99 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078821979 | CMS |
| Janssen Scientific Affairs, LLC | $1,907.50 | 02/14/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1078853896 | CMS |
| Karyopharm Therapeutics Inc. | $407.50 | 07/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1145537168 | CMS |
| Karyopharm Therapeutics Inc. | $815.00 | 11/05/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1145537170 | CMS |
| PFIZER INC. | $64,200.00 | 01/19/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1131583147 | CMS |
| PFIZER INC. | $47,700.00 | 01/23/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1131583677 | CMS |
| PFIZER INC. | $18,300.00 | 02/29/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1131583309 | CMS |
| PFIZER INC. | $1,200.00 | 04/04/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1131598972 | CMS |
| PFIZER INC. | $300.00 | 04/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1131600621 | CMS |
| PFIZER INC. | $74,700.00 | 05/09/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1131601129 | CMS |
| PFIZER INC. | $58,500.00 | 06/13/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1131625488 | CMS |
| PFIZER INC. | $2,700.00 | 07/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1131705899 | CMS |
| PFIZER INC. | $10,500.00 | 07/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1131705901 | CMS |
| PFIZER INC. | $4,000.00 | 08/28/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1131905173 | CMS |
| PFIZER INC. | $80,100.00 | 10/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1132032574 | CMS |
| PFIZER INC. | $122.69 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132133059 | CMS |
| PFIZER INC. | $62,200.00 | 10/23/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1132032576 | CMS |
| PFIZER INC. | $63,900.00 | 11/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1130894225 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.